Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7895 USD | +5.62% | -6.01% | -16.67% |
Financials (USD)
Sales 2024 * | 2M | Sales 2025 * | 3.33M | Capitalization | 57.48M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -106M | EV / Sales 2024 * | 28.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.2 x |
P/E ratio 2024 * |
-0.63
x | P/E ratio 2025 * |
-0.65
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.16% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | +5.62% | ||
1 week | -6.01% | ||
Current month | -4.24% | ||
1 month | -8.48% | ||
3 months | -6.19% | ||
6 months | +0.87% | ||
Current year | -16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 15-02-18 |
John Fowler
FOU | Founder | 52 | 15-02-18 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 16-10-31 |
Graham Cooper
CHM | Chairman | 54 | 17-09-30 |
Michael Kauffman
BRD | Director/Board Member | 60 | 16-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 0.7895 | +5.62% | 1,219,612 |
24-05-13 | 0.7475 | -3.26% | 1,525,124 |
24-05-10 | 0.7727 | -5.42% | 1,067,684 |
24-05-09 | 0.817 | -0.49% | 669,717 |
24-05-08 | 0.821 | -2.26% | 620,204 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.67% | 54.42M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- KZR Stock